Review





Similar Products

human fgf2  (MedChemExpress)
93
MedChemExpress human fgf2
Human Fgf2, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fgf2/pmc13011206-55-113-118?v=MedChemExpress
Average 93 stars, based on 1 article reviews
human fgf2 - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier
hnae  (Sino Biological)
95
Sino Biological hnae
Hnae, supplied by Sino Biological, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fgf2/pmc13019501-15-6-2?v=Sino+Biological
Average 95 stars, based on 1 article reviews
hnae - by Bioz Stars, 2026-07
95/100 stars
  Buy from Supplier
antibodies against fgf2  (Servicebio Inc)
86
Servicebio Inc antibodies against fgf2
Skin immunofluorescence staining and immunohistochemical analysis were performed in different treatment groups. A) Immunofluorescence staining images of NF200. β 3 -Tubulin. PGP9.5. CD31. VEGF and IL-6 in skin wounds on the 14th day after treatment. Scale = 400 μm. B) Immunohistochemical images of <t>FGF2</t> on day 14 in wound tissue. Scale = 400 μm. C) Images of the immunohistochemistry of AGEs. Scale bar = 400 μm. D) Fluorescence intensity of NF200. E) Fluorescence intensity of β 3 Tubulin. F) Fluorescence intensity of PGP9.5. G) CD31-labeled micro vessel density. H) Fluorescence intensity of VEGF. I) Fluorescence intensity of IL-6. J) Integrated option density (IOD) of FGF2. K) IOD of AGEs. Data are represented as mean ± SD (n = 3). Statistical analysis was performed using one-way analysis of variance (ANOVA) followed by Tukey's test ∗ p < 0.05. ∗∗ p < 0.01. ∗∗∗ p < 0.001. ∗∗∗∗ p < 0.0001.
Antibodies Against Fgf2, supplied by Servicebio Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fgf2/pmc13194551-412-20-26?v=Servicebio+Inc
Average 86 stars, based on 1 article reviews
antibodies against fgf2 - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier
basic fibroblast growth factor fgf2  (Thermo Fisher)
96
Thermo Fisher basic fibroblast growth factor fgf2
Skin immunofluorescence staining and immunohistochemical analysis were performed in different treatment groups. A) Immunofluorescence staining images of NF200. β 3 -Tubulin. PGP9.5. CD31. VEGF and IL-6 in skin wounds on the 14th day after treatment. Scale = 400 μm. B) Immunohistochemical images of <t>FGF2</t> on day 14 in wound tissue. Scale = 400 μm. C) Images of the immunohistochemistry of AGEs. Scale bar = 400 μm. D) Fluorescence intensity of NF200. E) Fluorescence intensity of β 3 Tubulin. F) Fluorescence intensity of PGP9.5. G) CD31-labeled micro vessel density. H) Fluorescence intensity of VEGF. I) Fluorescence intensity of IL-6. J) Integrated option density (IOD) of FGF2. K) IOD of AGEs. Data are represented as mean ± SD (n = 3). Statistical analysis was performed using one-way analysis of variance (ANOVA) followed by Tukey's test ∗ p < 0.05. ∗∗ p < 0.01. ∗∗∗ p < 0.001. ∗∗∗∗ p < 0.0001.
Basic Fibroblast Growth Factor Fgf2, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fgf2/pm42223721-93-20-25?v=Thermo+Fisher
Average 96 stars, based on 1 article reviews
basic fibroblast growth factor fgf2 - by Bioz Stars, 2026-07
96/100 stars
  Buy from Supplier
gene exp fgf2 gg03371371 m1  (Thermo Fisher)
94
Thermo Fisher gene exp fgf2 gg03371371 m1
Skin immunofluorescence staining and immunohistochemical analysis were performed in different treatment groups. A) Immunofluorescence staining images of NF200. β 3 -Tubulin. PGP9.5. CD31. VEGF and IL-6 in skin wounds on the 14th day after treatment. Scale = 400 μm. B) Immunohistochemical images of <t>FGF2</t> on day 14 in wound tissue. Scale = 400 μm. C) Images of the immunohistochemistry of AGEs. Scale bar = 400 μm. D) Fluorescence intensity of NF200. E) Fluorescence intensity of β 3 Tubulin. F) Fluorescence intensity of PGP9.5. G) CD31-labeled micro vessel density. H) Fluorescence intensity of VEGF. I) Fluorescence intensity of IL-6. J) Integrated option density (IOD) of FGF2. K) IOD of AGEs. Data are represented as mean ± SD (n = 3). Statistical analysis was performed using one-way analysis of variance (ANOVA) followed by Tukey's test ∗ p < 0.05. ∗∗ p < 0.01. ∗∗∗ p < 0.001. ∗∗∗∗ p < 0.0001.
Gene Exp Fgf2 Gg03371371 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fgf2/pmc13067120-0-23--1?v=Thermo+Fisher
Average 94 stars, based on 1 article reviews
gene exp fgf2 gg03371371 m1 - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier
fgf2  (Fisher Scientific)
86
Fisher Scientific fgf2
Skin immunofluorescence staining and immunohistochemical analysis were performed in different treatment groups. A) Immunofluorescence staining images of NF200. β 3 -Tubulin. PGP9.5. CD31. VEGF and IL-6 in skin wounds on the 14th day after treatment. Scale = 400 μm. B) Immunohistochemical images of <t>FGF2</t> on day 14 in wound tissue. Scale = 400 μm. C) Images of the immunohistochemistry of AGEs. Scale bar = 400 μm. D) Fluorescence intensity of NF200. E) Fluorescence intensity of β 3 Tubulin. F) Fluorescence intensity of PGP9.5. G) CD31-labeled micro vessel density. H) Fluorescence intensity of VEGF. I) Fluorescence intensity of IL-6. J) Integrated option density (IOD) of FGF2. K) IOD of AGEs. Data are represented as mean ± SD (n = 3). Statistical analysis was performed using one-way analysis of variance (ANOVA) followed by Tukey's test ∗ p < 0.05. ∗∗ p < 0.01. ∗∗∗ p < 0.001. ∗∗∗∗ p < 0.0001.
Fgf2, supplied by Fisher Scientific, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fgf2/pmc13196128-80-5-6?v=Fisher+Scientific
Average 86 stars, based on 1 article reviews
fgf2 - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier
gene exp fgf2 hs00266645 m1  (Thermo Fisher)
99
Thermo Fisher gene exp fgf2 hs00266645 m1
Myofibroblast activation in ISG15-deficient cells. (A) Spatial expression and intensity levels of two myofibroblast markers ( ACTA2 and COL5A1 ). (B) Relative expression of various myofibroblast markers for clusters 1 and 5 separated by sample biopsy. (C) Percentage of total spots that express TGFβ in the entire biopsy, within CD68 + spots only, and within myofibroblast cluster 5. (D) Significance of pathway enrichment for clusters 0, 1, 5, 3, 7, and 9 generated by MSigDB Hallmark 2020 and BioPlanet 2019 analysis from Enrichr. Adjusted P values are shown. (E) Relative RNA levels of myofibroblast markers ( PDGFA , ITGB6 , <t>FGF2</t> ) following a 72-h treatment with 1,000 IU/ml IFNα2b, 10 ng/ml TGFβ, or both of WT and ISG15 KO lung epithelial cells (A549). (F) Percentage of cells undergoing EMT upon TGFβ/IFNα stimulation. (G) Relative RNA levels of myofibroblast markers ( PDGFA , ITGB6 , FGF2 ) following a 5-day treatment with 1,000 IU/ml IFNα2b, 10 ng/ml TGFβ, or both of WT and ISG15 KO fibroblasts. (H) ACTA2 (myofibroblasts) IHC for lesion 1 and lesion 3. P values were calculated with two-tailed t test. *P < 0.05.
Gene Exp Fgf2 Hs00266645 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fgf2/pmc12931375-249-19--1?v=Thermo+Fisher
Average 99 stars, based on 1 article reviews
gene exp fgf2 hs00266645 m1 - by Bioz Stars, 2026-07
99/100 stars
  Buy from Supplier
basic fibroblast growth factor  (R&D Systems)
96
R&D Systems basic fibroblast growth factor
Myofibroblast activation in ISG15-deficient cells. (A) Spatial expression and intensity levels of two myofibroblast markers ( ACTA2 and COL5A1 ). (B) Relative expression of various myofibroblast markers for clusters 1 and 5 separated by sample biopsy. (C) Percentage of total spots that express TGFβ in the entire biopsy, within CD68 + spots only, and within myofibroblast cluster 5. (D) Significance of pathway enrichment for clusters 0, 1, 5, 3, 7, and 9 generated by MSigDB Hallmark 2020 and BioPlanet 2019 analysis from Enrichr. Adjusted P values are shown. (E) Relative RNA levels of myofibroblast markers ( PDGFA , ITGB6 , <t>FGF2</t> ) following a 72-h treatment with 1,000 IU/ml IFNα2b, 10 ng/ml TGFβ, or both of WT and ISG15 KO lung epithelial cells (A549). (F) Percentage of cells undergoing EMT upon TGFβ/IFNα stimulation. (G) Relative RNA levels of myofibroblast markers ( PDGFA , ITGB6 , FGF2 ) following a 5-day treatment with 1,000 IU/ml IFNα2b, 10 ng/ml TGFβ, or both of WT and ISG15 KO fibroblasts. (H) ACTA2 (myofibroblasts) IHC for lesion 1 and lesion 3. P values were calculated with two-tailed t test. *P < 0.05.
Basic Fibroblast Growth Factor, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fgf2/pmc13132546-182-33-37?v=R%26D+Systems
Average 96 stars, based on 1 article reviews
basic fibroblast growth factor - by Bioz Stars, 2026-07
96/100 stars
  Buy from Supplier
fgf2  (R&D Systems)
96
R&D Systems fgf2
Myofibroblast activation in ISG15-deficient cells. (A) Spatial expression and intensity levels of two myofibroblast markers ( ACTA2 and COL5A1 ). (B) Relative expression of various myofibroblast markers for clusters 1 and 5 separated by sample biopsy. (C) Percentage of total spots that express TGFβ in the entire biopsy, within CD68 + spots only, and within myofibroblast cluster 5. (D) Significance of pathway enrichment for clusters 0, 1, 5, 3, 7, and 9 generated by MSigDB Hallmark 2020 and BioPlanet 2019 analysis from Enrichr. Adjusted P values are shown. (E) Relative RNA levels of myofibroblast markers ( PDGFA , ITGB6 , <t>FGF2</t> ) following a 72-h treatment with 1,000 IU/ml IFNα2b, 10 ng/ml TGFβ, or both of WT and ISG15 KO lung epithelial cells (A549). (F) Percentage of cells undergoing EMT upon TGFβ/IFNα stimulation. (G) Relative RNA levels of myofibroblast markers ( PDGFA , ITGB6 , FGF2 ) following a 5-day treatment with 1,000 IU/ml IFNα2b, 10 ng/ml TGFβ, or both of WT and ISG15 KO fibroblasts. (H) ACTA2 (myofibroblasts) IHC for lesion 1 and lesion 3. P values were calculated with two-tailed t test. *P < 0.05.
Fgf2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fgf2/bio_rxiv__64898__2026__04__14__718471-135-11-14?v=R%26D+Systems
Average 96 stars, based on 1 article reviews
fgf2 - by Bioz Stars, 2026-07
96/100 stars
  Buy from Supplier
human fibroblast growth factor 2  (R&D Systems)
96
R&D Systems human fibroblast growth factor 2
Myofibroblast activation in ISG15-deficient cells. (A) Spatial expression and intensity levels of two myofibroblast markers ( ACTA2 and COL5A1 ). (B) Relative expression of various myofibroblast markers for clusters 1 and 5 separated by sample biopsy. (C) Percentage of total spots that express TGFβ in the entire biopsy, within CD68 + spots only, and within myofibroblast cluster 5. (D) Significance of pathway enrichment for clusters 0, 1, 5, 3, 7, and 9 generated by MSigDB Hallmark 2020 and BioPlanet 2019 analysis from Enrichr. Adjusted P values are shown. (E) Relative RNA levels of myofibroblast markers ( PDGFA , ITGB6 , <t>FGF2</t> ) following a 72-h treatment with 1,000 IU/ml IFNα2b, 10 ng/ml TGFβ, or both of WT and ISG15 KO lung epithelial cells (A549). (F) Percentage of cells undergoing EMT upon TGFβ/IFNα stimulation. (G) Relative RNA levels of myofibroblast markers ( PDGFA , ITGB6 , FGF2 ) following a 5-day treatment with 1,000 IU/ml IFNα2b, 10 ng/ml TGFβ, or both of WT and ISG15 KO fibroblasts. (H) ACTA2 (myofibroblasts) IHC for lesion 1 and lesion 3. P values were calculated with two-tailed t test. *P < 0.05.
Human Fibroblast Growth Factor 2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fgf2/pm41978430-44-25-30?v=R%26D+Systems
Average 96 stars, based on 1 article reviews
human fibroblast growth factor 2 - by Bioz Stars, 2026-07
96/100 stars
  Buy from Supplier

Image Search Results


Skin immunofluorescence staining and immunohistochemical analysis were performed in different treatment groups. A) Immunofluorescence staining images of NF200. β 3 -Tubulin. PGP9.5. CD31. VEGF and IL-6 in skin wounds on the 14th day after treatment. Scale = 400 μm. B) Immunohistochemical images of FGF2 on day 14 in wound tissue. Scale = 400 μm. C) Images of the immunohistochemistry of AGEs. Scale bar = 400 μm. D) Fluorescence intensity of NF200. E) Fluorescence intensity of β 3 Tubulin. F) Fluorescence intensity of PGP9.5. G) CD31-labeled micro vessel density. H) Fluorescence intensity of VEGF. I) Fluorescence intensity of IL-6. J) Integrated option density (IOD) of FGF2. K) IOD of AGEs. Data are represented as mean ± SD (n = 3). Statistical analysis was performed using one-way analysis of variance (ANOVA) followed by Tukey's test ∗ p < 0.05. ∗∗ p < 0.01. ∗∗∗ p < 0.001. ∗∗∗∗ p < 0.0001.

Journal: Materials Today Bio

Article Title: Multidimensional nano-ion composite hydrogel based on enzymatic blood glucose control, gas therapy and ion liquid permeation for repairing diabetic wounds

doi: 10.1016/j.mtbio.2026.103213

Figure Lengend Snippet: Skin immunofluorescence staining and immunohistochemical analysis were performed in different treatment groups. A) Immunofluorescence staining images of NF200. β 3 -Tubulin. PGP9.5. CD31. VEGF and IL-6 in skin wounds on the 14th day after treatment. Scale = 400 μm. B) Immunohistochemical images of FGF2 on day 14 in wound tissue. Scale = 400 μm. C) Images of the immunohistochemistry of AGEs. Scale bar = 400 μm. D) Fluorescence intensity of NF200. E) Fluorescence intensity of β 3 Tubulin. F) Fluorescence intensity of PGP9.5. G) CD31-labeled micro vessel density. H) Fluorescence intensity of VEGF. I) Fluorescence intensity of IL-6. J) Integrated option density (IOD) of FGF2. K) IOD of AGEs. Data are represented as mean ± SD (n = 3). Statistical analysis was performed using one-way analysis of variance (ANOVA) followed by Tukey's test ∗ p < 0.05. ∗∗ p < 0.01. ∗∗∗ p < 0.001. ∗∗∗∗ p < 0.0001.

Article Snippet: After routine deparaffinization, rehydration, and antigen retrieval, the sections were blocked and then incubated overnight at 4 °C with primary antibodies against FGF2 (1:500, GB113751 , Servicebio) and AGEs (1:200, bs-1158R, BIOSS).

Techniques: Immunofluorescence, Staining, Immunohistochemical staining, Immunohistochemistry, Fluorescence, Labeling

Myofibroblast activation in ISG15-deficient cells. (A) Spatial expression and intensity levels of two myofibroblast markers ( ACTA2 and COL5A1 ). (B) Relative expression of various myofibroblast markers for clusters 1 and 5 separated by sample biopsy. (C) Percentage of total spots that express TGFβ in the entire biopsy, within CD68 + spots only, and within myofibroblast cluster 5. (D) Significance of pathway enrichment for clusters 0, 1, 5, 3, 7, and 9 generated by MSigDB Hallmark 2020 and BioPlanet 2019 analysis from Enrichr. Adjusted P values are shown. (E) Relative RNA levels of myofibroblast markers ( PDGFA , ITGB6 , FGF2 ) following a 72-h treatment with 1,000 IU/ml IFNα2b, 10 ng/ml TGFβ, or both of WT and ISG15 KO lung epithelial cells (A549). (F) Percentage of cells undergoing EMT upon TGFβ/IFNα stimulation. (G) Relative RNA levels of myofibroblast markers ( PDGFA , ITGB6 , FGF2 ) following a 5-day treatment with 1,000 IU/ml IFNα2b, 10 ng/ml TGFβ, or both of WT and ISG15 KO fibroblasts. (H) ACTA2 (myofibroblasts) IHC for lesion 1 and lesion 3. P values were calculated with two-tailed t test. *P < 0.05.

Journal: Journal of Human Immunity

Article Title: Human ISG15 deficiency unveils impaired healing of ulcerations via type I interferon–mediated fibrosis

doi: 10.70962/jhi.20250011

Figure Lengend Snippet: Myofibroblast activation in ISG15-deficient cells. (A) Spatial expression and intensity levels of two myofibroblast markers ( ACTA2 and COL5A1 ). (B) Relative expression of various myofibroblast markers for clusters 1 and 5 separated by sample biopsy. (C) Percentage of total spots that express TGFβ in the entire biopsy, within CD68 + spots only, and within myofibroblast cluster 5. (D) Significance of pathway enrichment for clusters 0, 1, 5, 3, 7, and 9 generated by MSigDB Hallmark 2020 and BioPlanet 2019 analysis from Enrichr. Adjusted P values are shown. (E) Relative RNA levels of myofibroblast markers ( PDGFA , ITGB6 , FGF2 ) following a 72-h treatment with 1,000 IU/ml IFNα2b, 10 ng/ml TGFβ, or both of WT and ISG15 KO lung epithelial cells (A549). (F) Percentage of cells undergoing EMT upon TGFβ/IFNα stimulation. (G) Relative RNA levels of myofibroblast markers ( PDGFA , ITGB6 , FGF2 ) following a 5-day treatment with 1,000 IU/ml IFNα2b, 10 ng/ml TGFβ, or both of WT and ISG15 KO fibroblasts. (H) ACTA2 (myofibroblasts) IHC for lesion 1 and lesion 3. P values were calculated with two-tailed t test. *P < 0.05.

Article Snippet: The probes used were the following: TGFB1 Hs07289533_m1, ISG15 Hs01921425_s1, IFIT1 Hs03027069_s1, IFI27 Hs01086373_g1, SIGLEC1 Hs00988063_m1, MX1 Hs00895608_m1, FGF-2 Hs00266645_m1, ITGB6 Hs00168458_m1, PDGFA Hs00234994_m1.

Techniques: Activation Assay, Expressing, Generated, Two Tailed Test